Amgen
Amgen is a global biotechnology leader focused on discovering, developing, and delivering innovative human therapeutics for serious illnesses with high unmet medical needs. The company leverages advanced human genetics and biologics expertise to treat cardiovascular disease, oncology, inflammation, and rare diseases. Amgen operates as an independent biotechnology pioneer with a presence in approximately 100 countries.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Human Therapeutics
primaryThe company's sole operating segment focused on the discovery and commercialization of innovative medicines across various therapeutic areas including oncology, inflammation, and cardiometabolic health.
Repatha, UPLIZNA, IMDELLTRA, TEZSPIRE, TEPEZZA, TAVNEOS, MariTide
Hospitals, Specialty Pharmacies, Wholesale Distributors, Physicians
Segment Financials
Reportable Segment — R&D
View metricReportable Segment — Sales and marketing
View metricReportable Segment — G&A
View metricBusiness Overview
Competitive Position
A leading independent biotechnology company with a robust pipeline of first-in-class medicines and a significant global commercial footprint.
Geographies
Global, United States, European Union
Customer Segments
Patients, Healthcare Providers, Payors
Upstream Dependencies
Raw material suppliers, Clinical research organizations, Specialized laboratory equipment providers
Downstream Customers
Drug wholesalers, Retail pharmacies, Hospitals and clinics, Government health agencies
Competitors & Partners
Competitors
Regeneron Pharmaceuticals
REGN
Competitor in cardiovascular and inflammatory disease treatments.
Eli Lilly
LLY
Competitor in obesity and diabetes (GLP-1/GIP market).
Pfizer
PFE
Competitor in oncology and inflammation.
AbbVie
ABBV
Competitor in immunology and biosimilars
Roivant Sciences
ROIV
Competitor in immunology and inflammatory disease treatments
Revolution Medicines, Inc.
RVMD
Developer of KRAS(OFF) G12C inhibitor sotorasib
Subsidiaries
ChemoCentryx
Acquired in October 2022, developer of TAVNEOS.
Horizon Therapeutics
Acquired subsidiary providing rare disease treatments like TEPEZZA and UPLIZNA.
Amgen FAQ
Common questions about Amgen
Amgen is a global biotechnology leader focused on discovering, developing, and delivering innovative human therapeutics for serious illnesses with high unmet medical needs. The company leverages advanced human genetics and biologics expertise to treat cardiovascular disease, oncology, inflammation, and rare diseases. Amgen operates as an independent biotechnology pioneer with a presence in approximately 100 countries.
Amgen (AMGN) has a market capitalization of $183.12B and trades on NASDAQ.
Amgen generated $37.2B in trailing twelve-month revenue with net income of $7.8B, representing a net margin of 21.0%. Gross margin stands at 68.3%, with free cash flow of $8.6B. These figures are based on the Q1 2026 filing.
Amgen's key competitors include Regeneron Pharmaceuticals, Eli Lilly and Company, Pfizer, and others. These companies compete in similar markets and product categories.
Amgen has approximately 26,700 employees.